Cell Death and Disease (Jun 2023)

The pediatric leukemia oncoprotein NUP98-KDM5A induces genomic instability that may facilitate malignant transformation

  • Joan Domingo-Reinés,
  • Rosa Montes,
  • Adrián Garcia-Moreno,
  • Amador Gallardo,
  • Jose Manuel Sanchez-Manas,
  • Iván Ellson,
  • Mar Lamolda,
  • Chiara Calabro,
  • Jose Antonio López-Escamez,
  • Purificación Catalina,
  • Pedro Carmona-Sáez,
  • Pedro J. Real,
  • David Landeira,
  • Verónica Ramos-Mejia

DOI
https://doi.org/10.1038/s41419-023-05870-5
Journal volume & issue
Vol. 14, no. 6
pp. 1 – 12

Abstract

Read online

Abstract Pediatric Acute Myeloid Leukemia (AML) is a rare and heterogeneous disease characterized by a high prevalence of gene fusions as driver mutations. Despite the improvement of survival in the last years, about 50% of patients still experience a relapse. It is not possible to improve prognosis only with further intensification of chemotherapy, as come with a severe cost to the health of patients, often resulting in treatment-related death or long-term sequels. To design more effective and less toxic therapies we need a better understanding of pediatric AML biology. The NUP98-KDM5A chimeric protein is exclusively found in a particular subgroup of young pediatric AML patients with complex karyotypes and poor prognosis. In this study, we investigated the impact of NUP98-KDM5A expression on cellular processes in human Pluripotent Stem Cell models and a patient-derived cell line. We found that NUP98-KDM5A generates genomic instability through two complementary mechanisms that involve accumulation of DNA damage and direct interference of RAE1 activity during mitosis. Overall, our data support that NUP98-KDM5A promotes genomic instability and likely contributes to malignant transformation.